BRPI0922884A2 - compostos para tratamento de câncer - Google Patents
compostos para tratamento de câncerInfo
- Publication number
- BRPI0922884A2 BRPI0922884A2 BRPI0922884A BRPI0922884A BRPI0922884A2 BR PI0922884 A2 BRPI0922884 A2 BR PI0922884A2 BR PI0922884 A BRPI0922884 A BR PI0922884A BR PI0922884 A BRPI0922884 A BR PI0922884A BR PI0922884 A2 BRPI0922884 A2 BR PI0922884A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- treatment compounds
- compounds
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08253914 | 2008-12-08 | ||
| GB0914322A GB0914322D0 (en) | 2009-08-14 | 2009-08-14 | Compounds for treating cancer |
| PCT/GB2009/002848 WO2010067067A1 (en) | 2008-12-08 | 2009-12-08 | Compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0922884A2 true BRPI0922884A2 (pt) | 2018-11-06 |
Family
ID=41480203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0922884A BRPI0922884A2 (pt) | 2008-12-08 | 2009-12-08 | compostos para tratamento de câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8759520B2 (pt) |
| EP (1) | EP2373629B1 (pt) |
| JP (1) | JP5736318B2 (pt) |
| KR (1) | KR20110097932A (pt) |
| CN (1) | CN102307862A (pt) |
| AU (1) | AU2009326259A1 (pt) |
| BR (1) | BRPI0922884A2 (pt) |
| CA (1) | CA2747185A1 (pt) |
| EA (1) | EA201100874A1 (pt) |
| IL (1) | IL213398A0 (pt) |
| MX (1) | MX2011006000A (pt) |
| WO (1) | WO2010067067A1 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013001313A (es) * | 2010-08-05 | 2013-06-13 | Amgen Inc | Compuestos de bencimidazol y azabencimidazol que inhiben la cinasa del linfoma anaplasico. |
| AU2013205512B2 (en) * | 2010-08-05 | 2015-09-17 | Amgen Inc. | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| WO2013074518A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| JP6037396B2 (ja) | 2012-01-27 | 2016-12-07 | 国立大学法人富山大学 | セリンラセマーゼ阻害剤 |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN104072425B (zh) * | 2014-07-09 | 2016-12-07 | 大连理工大学 | 苯并咪唑类化合物及其应用 |
| CN104744375B (zh) * | 2015-02-10 | 2017-09-19 | 南开大学 | 一种胍类ntr1小分子拮抗剂 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| CN109503495B (zh) * | 2018-11-21 | 2020-07-31 | 徐州医科大学 | 一种2-亚胺苯并咪唑类化合物及医药用途 |
| WO2021061801A1 (en) * | 2019-09-24 | 2021-04-01 | Icahn School Of Medicine At Mt. Sinai | Bicyclic inhibitors of cbx chromodomains |
| CN114929689B (zh) | 2019-10-28 | 2024-08-27 | 百济神州有限公司 | Bcl-2抑制剂 |
| US12286430B2 (en) | 2020-04-15 | 2025-04-29 | Beigene, Ltd. | Bcl-2 inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU5062100A (en) * | 1999-06-14 | 2001-01-02 | Novo Nordisk A/S | Fviia/tf activity inhibiting compounds |
| JP2002155060A (ja) * | 2000-11-15 | 2002-05-28 | Japan Tobacco Inc | イミダゾール化合物及びその用途 |
| US7476688B2 (en) | 2001-04-19 | 2009-01-13 | Eisai R&D Management Co., Ltd. | Cyclic amidine derivatives |
| US7868028B2 (en) * | 2002-06-17 | 2011-01-11 | Fred Drasner | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2006074991A1 (en) | 2005-01-11 | 2006-07-20 | Neurosearch A/S | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| MX2007011292A (es) * | 2005-03-17 | 2007-11-07 | Tibotec Pharm Ltd | 1,3-dihidro-bencimidazol-2-ilidenaminas como inhibidores de replicacion de virus respiratorios sinciciales. |
| EP2757099B1 (en) | 2005-05-12 | 2017-08-23 | AbbVie Bahamas Limited | Apoptosis promoters |
| ES2389101T3 (es) | 2005-05-24 | 2012-10-23 | Abbott Laboratories | Promotores de apoptosis |
| JP2009523816A (ja) * | 2006-01-19 | 2009-06-25 | アボット・ラボラトリーズ | ２−イミノ−ベンズイミダゾール類 |
| US7981888B2 (en) * | 2007-04-16 | 2011-07-19 | Abbott Laboratories | 1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives |
-
2009
- 2009-12-08 US US13/132,429 patent/US8759520B2/en active Active
- 2009-12-08 EA EA201100874A patent/EA201100874A1/ru unknown
- 2009-12-08 BR BRPI0922884A patent/BRPI0922884A2/pt not_active IP Right Cessation
- 2009-12-08 KR KR1020117015706A patent/KR20110097932A/ko not_active Withdrawn
- 2009-12-08 CN CN2009801562643A patent/CN102307862A/zh active Pending
- 2009-12-08 JP JP2011539097A patent/JP5736318B2/ja active Active
- 2009-12-08 AU AU2009326259A patent/AU2009326259A1/en not_active Abandoned
- 2009-12-08 MX MX2011006000A patent/MX2011006000A/es unknown
- 2009-12-08 WO PCT/GB2009/002848 patent/WO2010067067A1/en not_active Ceased
- 2009-12-08 CA CA2747185A patent/CA2747185A1/en not_active Abandoned
- 2009-12-08 EP EP09771396.0A patent/EP2373629B1/en active Active
-
2011
- 2011-06-06 IL IL213398A patent/IL213398A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110312969A1 (en) | 2011-12-22 |
| AU2009326259A1 (en) | 2011-07-28 |
| WO2010067067A1 (en) | 2010-06-17 |
| JP5736318B2 (ja) | 2015-06-17 |
| US8759520B2 (en) | 2014-06-24 |
| KR20110097932A (ko) | 2011-08-31 |
| CN102307862A (zh) | 2012-01-04 |
| EP2373629A1 (en) | 2011-10-12 |
| IL213398A0 (en) | 2011-07-31 |
| EP2373629B1 (en) | 2013-04-10 |
| EA201100874A1 (ru) | 2012-01-30 |
| JP2012510984A (ja) | 2012-05-17 |
| MX2011006000A (es) | 2011-07-20 |
| CA2747185A1 (en) | 2010-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012005594A2 (pt) | tratamento de câncer | |
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| BRPI0910282A2 (pt) | Composto oxadiazo-antraceno para o tratamento de diabetes | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| DK2121139T3 (da) | Formulations for cancer treatment | |
| BRPI0813670A2 (pt) | Compostos para tratamento | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| PT2340042E (pt) | Métodos e composições para o tratamento de cancro | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
| BRPI0919127A2 (pt) | métodos para tratamento de água | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| DK2173831T3 (da) | Brøndbehandling | |
| EP2283862A4 (en) | ANTITUMOR AGENT | |
| IL213398A0 (en) | Compounds for treating cancer | |
| BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
| DK2147122T3 (da) | Enzymatisk kræftbehandling | |
| EP2277400A4 (en) | MAGNETIC THERAPY SHOE | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |